Key Highlights
- FDA has accepted two supplemental Biologics License Applications (sBLAs) for priority review covering KEYTRUDA and KEYTRUDA QLEX combined with Padcev.
- The regulatory submissions focus on treating muscle-invasive bladder cancer (MIBC) patients who qualify for cisplatin-based chemotherapy.
- FDA has established August 17, 2026, as the target decision deadline.
- The applications are supported by positive results from the Phase 3 KEYNOTE-B15 clinical study demonstrating enhanced survival benefits.
- Approval would mark the first perioperative therapeutic option for MIBC patients irrespective of cisplatin treatment eligibility.
Merck has secured another significant regulatory milestone for its flagship immunotherapy KEYTRUDA, as the FDA grants expedited review for two bladder cancer treatment applications.
Merck revealed on Monday that the FDA has accepted for priority review two supplemental Biologics License Applications involving KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph). Each therapy is under review when used alongside Padcev (enfortumab vedotin-ejfv) for treating muscle-invasive bladder cancer patients who can receive cisplatin-based chemotherapy regimens.
The regulatory agency established a Prescription Drug User Fee Act target decision deadline of August 17, 2026.
The priority review designation is granted to therapeutic candidates that demonstrate potential for significant advancement in addressing serious medical conditions. This classification generally reduces the evaluation period to approximately six months, contrasting with the conventional ten-month review cycle.
Clinical Trial Outcomes
Both regulatory submissions are underpinned by findings from the Phase 3 KEYNOTE-B15 clinical trial. The study demonstrated enhanced survival metrics among muscle-invasive bladder cancer patients receiving the combined KEYTRUDA and Padcev treatment regimen.
Merck refrained from disclosing detailed trial results in Monday’s statement, though the FDA’s priority review determination suggests the agency views the evidence as potentially transformative for clinical practice.
Presently, the KEYTRUDA plus Padcev combination holds regulatory approval for adult patients with locally advanced or metastatic urothelial cancer across the United States, European Union, Japan, and additional markets worldwide.
These new regulatory filings seek to broaden that indication into an earlier disease stage — specifically the muscle-invasive phase — where therapeutic interventions typically aim for cure rather than disease management.
Potentially Groundbreaking Treatment Designation
Should the FDA grant approval, the KEYTRUDA and KEYTRUDA QLEX combinations with Padcev would represent the inaugural perioperative treatment options for MIBC patients without regard to cisplatin treatment eligibility status.
This represents an important clinical advancement. The current approval for this combination covers MIBC patients who cannot tolerate cisplatin-based chemotherapy. These pending applications would extend treatment availability to cisplatin-eligible patients — substantially expanding the addressable patient population.
Perioperative therapy encompasses treatment administered surrounding surgical intervention, which represents the established care standard for muscle-invasive bladder cancer. Securing approval in this treatment setting with priority review status positions Merck favorably from a regulatory standpoint approaching the August decision milestone.
KEYTRUDA QLEX represents a subcutaneous formulation of pembrolizumab, enabling administration through injection beneath the skin rather than requiring intravenous infusion. This delivery method could provide practical advantages compared to traditional IV administration protocols.
Merck’s shares advanced 3.13% on Monday following the announcement. The August 17 target deadline now represents a critical milestone for investors monitoring the pharmaceutical company’s oncology development portfolio.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
